Diabetes

In a debate at the 2025 APhA Annual Meeting, speakers highlighted GLP-1s’ advantages in stroke prevention and weight loss vs SGLT2s’ superiority in heart failure, CV death reduction, and renal protection.

Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.

Health care professionals in the study found it challenging to manage the complexities of disordered eating in patients with type 1 diabetes alongside their other responsibilities.

An expert roundtable discussed what consumers and pharmacists should be aware of as compounded versions of glucagon-like peptide-1 receptor agonists continue to proliferate.

Community pharmacists are uniquely positioned to assist with diabetes management using CGM devices.

Treatment with HTD1801 resulted in significant reductions in the hemoglobin A1c level and improved key cardiometabolic and liver parameters.

The new data emphasize the fundamental differences in management and associated complications with each form of diabetes.

The t:slim X2 insulin pump and Tandem Mobi system both use Control-IQ.

Radon exposure during pregnancy was significantly linked to increased odds of gestational diabetes.

SkinTE could aid Wagner grade 1 diabetic foot ulcers by regenerating and activating the tissues surrounding the wound to heal it completely.

Diabetes management through insulin could play a significant role in preventing antibiotic resistance.

Age, body mass index, and male sex are also associated with the development of diabetes.

Diabetic macular edema (DME) is the leading cause of new blindness in the US.

Overall, there is no long-term increased risk of developing thyroid cancer after initiating treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, although there is a short-term increase.

Three experts from UPMC Health Plan highlight the importance of treating patients’ physical, mental, and social health when managing diabetes, rather than the disease alone.

The diabetes treatment landscape is rapidly evolving, with new combination therapies and oral GLP-1 medications, positioning pharmacists to have an important role in personalizing care.

Glucose monitoring can help providers and pharmacists optimize medication management for personalized diabetes care.

Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, discusses the pharmacists role in diabetes care.

Pharmacy Times interviews Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, about glucagon-like peptide-1 receptors for diabetes treatment.

Limited access to healthy food in redlined communities contributes to higher rates of chronic disease and reduced life expectancy.

Age, frequent snoring, hypertension, and poor glycemic control are associated with excessive daytime sleepiness.

However, the effects on patient-reported outcomes were inconclusive when compared with self-monitoring blood glucose or the usual care.

Despite the explosion of public interest in these drugs, ongoing shortages and debates over compounding made access difficult.

The approval of the generic to liraglutide injection, currently in shortage, could help increase patient access to the type 2 diabetes treatment.

Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.